Drs Lunning and Kamdar spotlight the design of the POLARIX trial, the ways in which its results have changed their practice when treating patients with DLBCL, and the importance of further research investigating the molecular heterogeneity of this disease to determine potential causes of early relapse with pola-R-CHP.